期刊文献+

脂质体携载前列腺素E1对冠心病合并糖尿病患者发生造影剂肾病的预防作用 被引量:4

Preventive effect of prostaglandin E1 on contrast medium-induced nephropathy in patients with coronary disease combined with diabetes meilitus
原文传递
导出
摘要 目的探讨脂质体携载前列腺素E1(PGE1)对冠心病合并糖尿病的患者发生造影剂肾病的预防作用。方法选取行冠脉造影或介入治疗的合并糖尿病的冠心病患者198例,随机分为对照组和PGE1组。PGE1组在常规治疗的基础上予PGE120μg+生理盐水20ml静脉注射,1次/d,共10d,比较两组造影前、造影后48h、5d血肌酐(Scr)、尿素(BUN)、胱抑素C(CysC)水平及造影剂肾病发生率等。结果造影后48h、5dScr、BUN、CysC等在PGE1组分别为(113.92±54.89)μmmol/L、(7.85±4.05)mmol/L、(1.38±0.34)mg/L和(86.72±35.26)μmmol/L、(6.61±3.09)mmol/L、(1.29±0.29)mg/L优于对照组(129.22±50.18)μmmol/L、(9.28±3.95)mmol/L、(1.56±0.23)mg/L和(109.83±31.76)μmmol/L、(8.07±3.11)mmol/L、(1.37±0.21)mg/L,差异有统计学意义(均P〈0.05)。经直线相关分析,造影剂剂量与BUN、Scr呈显著正相关(r=0.74,P〈0.05;r=0.82,P〈0.01)。结论PGE1对冠心病合并糖尿病的患者发生造影剂肾病有预防作用。 Objective To study whether prostaglandin E1 (LipoPGE1) could prevent contrast mediuminduced nephropathy (CIN) in patients with coronary heart disease (CHD) plus diabetes mellitus type 2 (DM). Methods Total 198 CHD patients with DM received coronary angiography (CAG) or PCI were randomly divided into PGE1 group and control group. All patients received routine treatment, and the PGE1 group also received 20 ml normal saline and 20 μg PGE1 (intravenous injection , 1 time/d) for 10 days. The rate of CIN and the level of serum urea nitrogen (BUN), creatinine (Scr), cystatin C (Cys C) were measured before and 48 hours and 5 days after contrast medium administration. Results The level of Scr, BUN and Cys C were lower in PGE1 group [(113.92±54.89)μmmol/L、(7.85±4.05)mmol/L、(1.38±0.34)mg/L] for 48 hours and [(86.72±35.26)μmmol/L、(6.61±3.09)mmol/L、(1.29±0.29)mg/L] for 5 days than in control group [129.22±50.18)μmmol/L、(9.28±3.95)mmol/L、(1.56±0.23)mg/L] for 48 hours and [(109.83±31.76)μmmol/L、(8.07±3.11)mmol/L、(1.37±0.21)mg/L] for 5 days (all P〈0. 05). The dose of contrast-medium was positively correlated with the level of Scr and BUN (r=0. 74,P〈0. 05 and r =0.82,P〈0.01, respectively). The patientsr renal function in the PGE1 group was better than in control group after contrast-medium administration (P 〈0.05) . BUN and Scr were positively correlated with the volume of contrast-medium (r= 0.74, P〈0.05, r=0.82, P〈0.01). Conclusions PGE1 may prevent contrast medium-induced nephropathy in patients with CHD combined with DM.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2011年第10期830-832,共3页 Chinese Journal of Geriatrics
关键词 前列腺素E1 冠心病 糖尿病 2型 造影剂 Prostaglandin El Coronary disease Diabetes mellitus, type 2 Contrast media
  • 相关文献

参考文献10

  • 1Castini D,Lucreziotti S, Bosotti L, et al. Prevention of contrast-induced nephropathy: a single center randomized study. Clinical Cardiology, 2010, 33: E63-E68.
  • 2ZuoL, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis, 2005,45: 463-472.
  • 3Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast- induced nephropathy and mortality. Ann Intern Med, 2009,150..170-177.
  • 4Pucelikova T,Dangas G, Mehran R, et al. Contrast - induced nephropathy. Catheterization and Cardiovascular Interventions, 2008,71 : 62-72.
  • 5中国医师协会心血管内科医师分会,中国老年学会心脑血管专业委员会,中国医师协会循证医学专业委员会.对比剂肾病中国专家共识[S].心血管疾病防治指南和共识,2009:257-294.
  • 6Senoo T,Motohiro M, Kamihata H, et al. Contrast- induced nephropathy in patients undergoing emergency pereutaneous acute coronary syndrome 624-628. coronary intervention for Am J Cardiol, 2010, 105:.
  • 7La Manna G,Pancaldi LG, Capecchi A, et al. Risk :for contrast nephropathy in patients undergoing coronarography. Artificial Organs, 2010, 34: 193- 199.
  • 8Cronin RE. Contrast-induced nephropathy: pathogenesis and prevention. Pediatric Nephrology (Germany),2010, 25: 191-204.
  • 9Fulvio S, Andy A, Christoph RB, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol, 2006, 98(6A): 14-20.
  • 10Goldenberg I, Matetzky S. Nephropathy induced by contrast media., pathogenesis, risk factors and preventive strategies. CMA J, 2005,172 : 1461-1471.

同被引文献52

  • 1徐蓉,夏进东,金川连,沈旭峰,毛建强.前列地尔注射液对心功能不全患者冠脉介入术后对比剂肾病的影响[J].医学临床研究,2012,29(6). 被引量:5
  • 2Bao H, Ge Y,Zhuang S, et al. Inhibition of glycogen synthase kinase- 3B prevents NSAID- induced acute kidney injury J] .Kidney International, 2012,81 (7) :662-673.
  • 3Feitoza C Q,Semedo P, Goncalves G M, et al. Modulation of inflammatory response by selective inhibition of cyclooxygen- ase-1 and cyc]ooxygenase-2 in acute kidney injuryE J. In- flammation Research, 2010,59 (3) : 167-175.
  • 4Osthoff M, Trendelenburg M. Impact of mannose-binding leetin deficiency on radiocontrast-induced renal dysfunction [J]. Biomed Res Int, 2013,2013 : 962695.
  • 5Solomon R, Dauerman HL. Contrast-induced acute kidney injury [J]. Circulation, 2010,122(23) :2451-2455.
  • 6Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality[J]. Am J Nephrol, 2009,29(2) : 136-144.
  • 7Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/ AHA/SCAI guideline for percutaneous coronary intervention a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [ J ]. Circulation, 2011,124 ( 23 ) : e574-e651.
  • 8Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J]. Control Clin Trials, 1996, 17(1) : 1-12.
  • 9Li WH, Li DY, Qian WH, et al. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention [J]. Int Urol Nephrol, 2014,46(4) :781-786.
  • 10Xu RH, Ma GZ, Cai ZX, et al. Combined use of hydration and Alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients [J]. Exo Ther Med. 2013.6(4) :863-867.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部